Teva Pharmaceutical Industries Limited (TEVA) financial statements and ratios from SEC XBRL: revenue $17.3B (TTM), net margin 8.2%, revenue growth -0.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $17.26B |
| Revenue (TTM) | $17.3B |
| Net Margin | 8.2% |
| Return on Equity | 9.1% |
| Operating Margin (TTM) | 9.3% |
| Debt / Equity | 0.58 |
| Current Ratio | 0.88 |
| Net Debt / EBITDA | 0.3 |
| Interest Coverage | 1.8 |
| Revenue Growth (YoY) | -0.8% |
| EPS Growth (YoY) | -296.0% |
| FCF Growth (YoY) | 134.4% |
| Altman Z-Score | 0.90 (distress) |
| Piotroski F-Score | 8/9 |
| Piotroski checks passed | 8 of 9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.6 |
TEVA overview · TEVA earnings · TEVA KPIs · TEVA documents · TEVA ownership · TEVA peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.